Biosolution Co.Ltd - Asset Resilience Ratio
Biosolution Co.Ltd (086820) has an Asset Resilience Ratio of 0.34% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Biosolution Co.Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Biosolution Co.Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Biosolution Co.Ltd.
Liquid Assets Composition Over Time
This chart breaks down Biosolution Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Biosolution Co.Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩211.66 Million | 0.34% |
| Total Liquid Assets | ₩211.66 Million | 0.34% |
Asset Resilience Insights
- Limited Liquidity: Biosolution Co.Ltd maintains only 0.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biosolution Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Biosolution Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Biosolution Co.Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Biosolution Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.27% | ₩14.35 Billion ≈ $9.72 Million |
₩67.46 Billion ≈ $45.72 Million |
-19.56pp |
| 2023-12-31 | 40.83% | ₩37.71 Billion ≈ $25.56 Million |
₩92.35 Billion ≈ $62.58 Million |
-38.53pp |
| 2022-12-31 | 79.36% | ₩72.80 Billion ≈ $49.34 Million |
₩91.73 Billion ≈ $62.16 Million |
-8.65pp |
| 2021-12-31 | 88.01% | ₩83.08 Billion ≈ $56.30 Million |
₩94.40 Billion ≈ $63.98 Million |
+15.31pp |
| 2020-12-31 | 72.70% | ₩36.20 Billion ≈ $24.54 Million |
₩49.80 Billion ≈ $33.75 Million |
-5.43pp |
| 2019-12-31 | 78.13% | ₩40.48 Billion ≈ $27.43 Million |
₩51.81 Billion ≈ $35.11 Million |
-6.71pp |
| 2018-12-31 | 84.85% | ₩44.85 Billion ≈ $30.40 Million |
₩52.87 Billion ≈ $35.83 Million |
+54.06pp |
| 2017-12-31 | 30.79% | ₩2.27 Billion ≈ $1.54 Million |
₩7.38 Billion ≈ $5.00 Million |
+1.51pp |
| 2016-12-31 | 29.27% | ₩2.58 Billion ≈ $1.75 Million |
₩8.82 Billion ≈ $5.98 Million |
-1.40pp |
| 2015-12-31 | 30.67% | ₩3.01 Billion ≈ $2.04 Million |
₩9.80 Billion ≈ $6.64 Million |
-- |
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more